Development and validation of an attenuated Mycoplasma hyopneumoniae aerosol vaccine

Feng, Zhixin; Wei, Yiran; Li, Guilan; Wan, Xiu‐Feng; Pharr, G. T.; Wang, Zhanwei; Kong, Min; Gao, Yuan; Bai, Fangfang; Liu, Maojun; Xiong, Qiyan; Wu, Xiaoyun; Shao, Guoqing

doi:10.1016/j.vetmic.2013.08.012

Cited by 33 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been proved that the antigen-specific SIgA induced by pathogens or vaccines, constitutes a first-line defense and confers to effective protections against mucosal infectious diseases, primarily by immune exclusion of viral or bacterial pathogens or neutralizing microbial toxins and pathogens [43][44][45]. In this study, the levels of SIgA in pig BALFs increased significantly at 21 DPI (Fig 5) while almost no IgG and IgM were detected in sera (S3A Fig), indicating mucosal immune was the main immune responses to Mycoplasma infections as reported previously [46,47]. In airways, antigen-specific SIgA is released by epithelial cells after the association of secretory component (SC) with polymeric IgA, which is produced by IgA-secreting plasma cells differentiated from IgA+ effector B cells.…”

Section: Discussionsupporting

confidence: 83%

Cathepsin L promotes secretory IgA response by participating in antigen presentation pathways during Mycoplasma Hyopneumoniae infection

et al. 2019

View full text Add to dashboard Cite

Cathepsin L (CTSL) has been proved to help contain leishmaniasis and mycoplasma infection in mice by supporting cellular immune responses, but the regulatory functions of CTSL on mucosal immune responses haven’t been tested and remain undefined. Here, we investigated the effects of CTSL on SIgA responses and invariant chain (Ii) degradations in the co-cultured swine dendritic cells (DCs) and B cells system in vitro . When the cells system were transfected with vector CTSL-GFP or incubated with recombinant CTSL (rCTSL) before they were infected with Mycoplasma hyopneumoniae ( M . hp ), SIgA significantly increased and Ii chain was degraded into smaller intermediates, while SIgA decreased when CTSL was knockdown or inhibited with E64. To confirm the SIgA responses promoted by CTSL contribute to the resistance to mycoplasma pneumonia, pigs injected with rCTSL before they were challenged with M . hp , showed milder clinical symptoms and histopathological damage of lungs, less mycoplasma burden together with higher secretion of SIgA, percentages of CD4 + T cells and level of MHC II molecules comparing with the group without rCTSL. Collectively, these results suggested that rCTSL could provide effective protection for piglets against mycoplasma pneumonia by enhancing M . hp -specific mucosal immune responses through its role in antigen presentation by processing the invariant chain.

show abstract

Section: Discussionsupporting

confidence: 83%

Cathepsin L promotes secretory IgA response by participating in antigen presentation pathways during Mycoplasma Hyopneumoniae infection

et al. 2019

View full text Add to dashboard Cite

show abstract

“…It is a one‐shot vaccine combined with PCV2 that can be administered to piglets from 3 weeks of age onwards. In addition, attenuated vaccines against M. hyopneumoniae have been licensed in China (Feng et al., ) and Mexico. The vaccine in Mexico is a thermosensitive mutant of M. hyopneumoniae (VaxSafe MHYO, Avimex).…”

Section: Prevention and Controlmentioning

confidence: 99%

Update onMycoplasma hyopneumoniaeinfections in pigs: Knowledge gaps for improved disease control

Maes

Sibila

Kuhnert

et al. 2017

Transbound Emerg Dis

214

229

View full text Add to dashboard Cite

SummaryMycoplasma hyopneumoniae (M. hyopneumoniae) is the primary pathogen of enzootic pneumonia, a chronic respiratory disease in pigs. Infections occur worldwide and cause major economic losses to the pig industry. The present paper reviews the current knowledge on M. hyopneumoniae infections, with emphasis on identification and analysis of knowledge gaps for optimizing control of the disease. Close contact between infected and susceptible pigs is the main route of M. hyopneumoniae transmission. Management and housing conditions predisposing for infection or disease are known, but further research is needed to better understand M. hyopneumoniae transmission patterns in modern pig production systems, and to assess the impor-

show abstract

“…A list of these vaccines is provided in Table 1. A live-attenuated vaccine against M. hyopneumoniae is only available in China [65]. While these vaccines have been licensed and accepted by swine, poultry, and cattle producers in many countries, it remains to be seen whether North American or European producers, especially dairy farmers, would accept this kind of vaccine against M. bovis.…”

Section: Live-attenuated Vaccinesmentioning

confidence: 99%

Status of the development of a vaccine against Mycoplasma bovis

Perez-Casal¹,

Prysliak²,

Maina³

et al. 2017

Vaccine

View full text Add to dashboard Cite

Development and validation of an attenuated Mycoplasma hyopneumoniae aerosol vaccine

Cited by 33 publications

References 30 publications

Cathepsin L promotes secretory IgA response by participating in antigen presentation pathways during Mycoplasma Hyopneumoniae infection

Cathepsin L promotes secretory IgA response by participating in antigen presentation pathways during Mycoplasma Hyopneumoniae infection

Update onMycoplasma hyopneumoniaeinfections in pigs: Knowledge gaps for improved disease control

Status of the development of a vaccine against Mycoplasma bovis

Contact Info

Product

Resources

About